Logo image of PHARM.AS

PHARMING GROUP NV (PHARM.AS) Stock Price, Quote, News and Overview

AMS:PHARM - Euronext Amsterdam - NL0010391025 - Common Stock - Currency: EUR

0.9835  +0.03 (+2.98%)

PHARM.AS Quote, Performance and Key Statistics

PHARMING GROUP NV

AMS:PHARM (5/30/2025, 7:00:00 PM)

0.9835

+0.03 (+2.98%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High0.99
52 Week Low0.65
Market Cap67.26M
Shares68.39M
Float67.38M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-31 2025-07-31
IPO07-02 1998-07-02


PHARM.AS short term performance overview.The bars show the price performance of PHARM.AS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30

PHARM.AS long term performance overview.The bars show the price performance of PHARM.AS in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 20

The current stock price of PHARM.AS is 0.9835 EUR. In the past month the price increased by 23.48%. In the past year, price increased by 19.87%.

PHARMING GROUP NV / PHARM Daily stock chart

PHARM.AS Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 18.04 288.63B
AMG.DE AMGEN INC 13.76 135.45B
1AMGN.MI AMGEN INC 13.73 128.96B
GIS.DE GILEAD SCIENCES INC 14.18 120.45B
1GILD.MI GILEAD SCIENCES INC 13.99 119.24B
VX1.DE VERTEX PHARMACEUTICALS INC N/A 99.93B
ARGX.BR ARGENX SE 107.29 30.92B
22UA.DE BIONTECH SE-ADR N/A 20.29B
IDP.DE BIOGEN INC 8.24 16.85B
1MRNA.MI MODERNA INC N/A 9.15B
0QF.DE MODERNA INC N/A 8.90B
BIO.DE BIOTEST AG N/A 1.69B

About PHARM.AS

Company Profile

PHARM logo image Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 426 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Company Info

PHARMING GROUP NV

Darwinweg 24

Leiden ZUID-HOLLAND NL

Employees: 426

PHARM Company Website

PHARM Investor Relations

Phone: 31715247400

PHARMING GROUP NV / PHARM.AS FAQ

What is the stock price of PHARMING GROUP NV today?

The current stock price of PHARM.AS is 0.9835 EUR. The price increased by 2.98% in the last trading session.


What is the ticker symbol for PHARMING GROUP NV stock?

The exchange symbol of PHARMING GROUP NV is PHARM and it is listed on the Euronext Amsterdam exchange.


On which exchange is PHARM.AS stock listed?

PHARM.AS stock is listed on the Euronext Amsterdam exchange.


What is the price forecast or stock price prediction for PHARMING GROUP NV stock?

14 analysts have analysed PHARM.AS and the average price target is 6.24 EUR. This implies a price increase of 534.52% is expected in the next year compared to the current price of 0.9835. Check the PHARMING GROUP NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PHARMING GROUP NV worth?

PHARMING GROUP NV (PHARM.AS) has a market capitalization of 67.26M EUR. This makes PHARM.AS a Micro Cap stock.


How many employees does PHARMING GROUP NV have?

PHARMING GROUP NV (PHARM.AS) currently has 426 employees.


What are the support and resistance levels for PHARMING GROUP NV (PHARM.AS) stock?

PHARMING GROUP NV (PHARM.AS) has a support level at 0.96. Check the full technical report for a detailed analysis of PHARM.AS support and resistance levels.


Is PHARMING GROUP NV (PHARM.AS) expected to grow?

The Revenue of PHARMING GROUP NV (PHARM.AS) is expected to grow by 14.32% in the next year. Check the estimates tab for more information on the PHARM.AS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy PHARMING GROUP NV (PHARM.AS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PHARMING GROUP NV (PHARM.AS) stock pay dividends?

PHARM.AS does not pay a dividend.


When does PHARMING GROUP NV (PHARM.AS) report earnings?

PHARMING GROUP NV (PHARM.AS) will report earnings on 2025-07-31.


What is the Price/Earnings (PE) ratio of PHARMING GROUP NV (PHARM.AS)?

PHARMING GROUP NV (PHARM.AS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.02).


PHARM.AS Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to PHARM.AS. When comparing the yearly performance of all stocks, PHARM.AS is one of the better performing stocks in the market, outperforming 88.19% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PHARM.AS Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to PHARM.AS. PHARM.AS has an average financial health and profitability rating.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PHARM.AS Financial Highlights

Over the last trailing twelve months PHARM.AS reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS decreased by -50% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -3.5%
ROE -6.59%
Debt/Equity 0.52
Chartmill High Growth Momentum
EPS Q2Q%-15.79%
Sales Q2Q%42.29%
EPS 1Y (TTM)-50%
Revenue 1Y (TTM)24.13%

PHARM.AS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 89% to PHARM.AS. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of 183.09% and a revenue growth 14.32% for PHARM.AS


Ownership
Inst Owners15.1%
Ins Owners1.49%
Short Float %N/A
Short RatioN/A
Analysts
Analysts88.57
Price Target6.24 (534.47%)
EPS Next Y183.09%
Revenue Next Year14.32%